Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMACare: lutetium [177Lu] vipivotide tetraxetan alone or with androgen receptor pathway inhibitor in PSMA-positive castration-resistant prostate cancer
NL-OMON59949Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoint: PSA response rate. Started Jan 2024; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetanenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59949.